ArticlePediatric nephrology (Berlin, Germany)2006
The effect of aldosterone blockade in patients with Alport syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Clinical practice recommendations for the management of Alport syndrome: a joint statement of the Korean Society of Nephrology and the Korean Society of Pediatric Nephrology.Kidney research and clinical practice · 2026Article
- Review
- Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease.Journal of clinical medicine · 2021Article
- Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome.Journal of clinical medicine · 2021Article
- Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.Pediatric nephrology (Berlin, Germany) · 2021Review
- A child with familial glomerulonephritis: Answers.Pediatric nephrology (Berlin, Germany) · 2020Article
- HeterozygousFrontiers in pediatrics · 2018Article
- Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.Pediatric nephrology (Berlin, Germany) · 2014Review
- Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.Pediatric nephrology (Berlin, Germany) · 2013Article
- An update on the pathomechanisms and future therapies of Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2013Review
- Article
- Alport Syndrome: De Novo Mutation in the COL4A5 Gene Converting Glycine 1205 to Valine.Clinical medicine insights. Pediatrics · 2012Article
- Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity.Pediatric nephrology (Berlin, Germany) · 2011Article
- Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.Pediatric nephrology (Berlin, Germany) · 2009Review
- Drugs controlling proteinuria of patients with Alport syndrome.World journal of pediatrics : WJP · 2009Article
- Treatment of hypertension in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2009Review
- Hypertension in children and adolescents: an approach to management of complex hyper-tension in pediatric patients.Current hypertension reports · 2009Review
- Familial hematuria.Pediatric nephrology (Berlin, Germany) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies indicate that adding the mineralocorticoid receptor antagonist spironolactone (SP) to angiotensin converting enzyme inhibitors (ACEI) or ACEI and angiotensin receptor blocker (ARB), which is known as a triple blockade, enhances the more beneficial effects on urinary protein excretion of patients with chronic kidney diseases. In this study, we explored the effects of SP on urinary protein excretion in patients with Alport syndrome featuring persistent proteinuria in spite of the long-term use of ACEI (lisinopril) or both ACEI and ARB (candesartan). Five patients with Alport syndrome were enrolled and SP treatment (25 mg/day) was started. At the start of SP administration, all patients showed good renal function and none of them suffered from hypertension. We decided to assess the effect of SP by determining the morning urinary protein/creatinine ratio (U-P/C) and estimated glomerular filtration rate (EGFR). After SP treatment was started, U-P/C was significantly reduced at 3, 6, 12 and 18 months, while EGFR did not change. The drop in systolic and diastolic blood pressure was statistically significant and serum potassium level was slightly elevated. None of the patients showed signs of severe hyperkalemia (>5.0 mEq/l). These results suggest that aldosterone receptor blockade combined with ACEI and ARB therapy offers a valuable adjuvant treatment for the reduction of proteinuria in patients with Alport syndrome as in those with other chronic kidney diseases. SP can thus be expected to constitute a good renoprotective agent for Alport syndrome. These preliminary data indicate that large-scale trials of this therapy should be done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.